PALATINE, IL--(Marketwire - November 01, 2012) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company plans to report financial results for the third quarter of 2012 following the close of financial markets on Tuesday, November 6, 2012. The company will host a conference call to discuss the results on Wednesday, November 7, 2012 at 8:30 a.m. ET.
To participate in the live conference call, please dial 888-359-3624 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 4454583.
A replay of the call will be available beginning November 8, 2012 at 11:30 a.m. ET and ending on November 20, 2012 on the company’s website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 4454583.
About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE™ technologies. In June 2011, the U.S. Food and Drug Administration approved OXECTA® which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products including other opioids and its IMPEDE™ technology for pseudoephedrine hydrochloride products.
The trademark OXECTA® is owned by Pfizer Inc.
Contact:
for Acura Investor Relations
Email Contact
847-705-7709
for Acura Media Relations
Email Contact
847-705-7709
